Fig. 5From: Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case reportCT revealed a decreased size and number of lung nodules. Lung metastases in the entire lung were noted (a, b, c); CT scan after two cycles (d, e, f), four cycles (g, h, i) and six cycles (j, k, l) of pembrolizumab plus gemcitabine, the masses were markedly smaller and a marked response lasting for over 7 monthsBack to article page